Rubius Therapeutics (NASDAQ:RUBY – Get Rating) and Cardiol Therapeutics (NASDAQ:CRDL – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.
Valuation & Earnings
This table compares Rubius Therapeutics and Cardiol Therapeutics' revenue, earnings per share (EPS) and valuation.
Get
Rubius Therapeutics alerts:
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| Rubius Therapeutics | N/A | N/A | -$179.67 million | ($2.38) | -0.03 |
| Cardiol Therapeutics | $60,000.00 | 563.12 | -$25.24 million | ($0.38) | -1.39 |
Cardiol Therapeutics has higher revenue and earnings than Rubius Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Rubius Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
76.1% of Rubius Therapeutics shares are held by institutional investors. Comparatively, 7.5% of Cardiol Therapeutics shares are held by institutional investors. 52.8% of Rubius Therapeutics shares are held by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Rubius Therapeutics and Cardiol Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| Rubius Therapeutics | N/A | -212.29% | -86.74% |
| Cardiol Therapeutics | N/A | -44.32% | -38.18% |
Analyst Ratings
This is a summary of current ratings and target prices for Rubius Therapeutics and Cardiol Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| Rubius Therapeutics | 0 | 3 | 1 | 0 | 2.25 |
| Cardiol Therapeutics | 0 | 0 | 0 | 0 | N/A |
Rubius Therapeutics currently has a consensus price target of $5.00, indicating a potential upside of 7,964.52%. Cardiol Therapeutics has a consensus price target of $4.00, indicating a potential upside of 658.87%. Given Rubius Therapeutics' higher probable upside, research analysts plainly believe Rubius Therapeutics is more favorable than Cardiol Therapeutics.
Risk and Volatility
Rubius Therapeutics has a beta of 2.51, meaning that its share price is 151% more volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of -0.13, meaning that its share price is 113% less volatile than the S&P 500.
Summary
Rubius Therapeutics beats Cardiol Therapeutics on 6 of the 11 factors compared between the two stocks.
About Rubius Therapeutics
(Get Rating)
Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan on April 26, 2013 and is headquartered in Foxboro, MA.
About Cardiol Therapeutics
(Get Rating)
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ""ARCHER"" trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
